中新网北京9月16日电 (陶思阅)9月15日，记者走进中国(北京)自由贸易试验区(以下简称"北京自贸试验 区")，看到其以制度创新为核心，对接国际高标准经贸规则的诸多实践，推进各项先行先试举措落地， 为吸引外资打好政策"提前量"。 据介绍，北京中关村科学城区域重点发展新一代信息技术、生命与健康、科技服务等产业，打造数字经 济试验区、全球创业投资中心、科技体制改革先行示范区。国际商务服务片区重点发展数字贸易、文化 贸易、商务会展、医疗健康、国际寄递物流、跨境金融等产业，打造临空经济创新引领示范区。 作为全国首批对接国际高标准推进制度型开放的试点，北京自贸试验区落实30余项试点措施。 同时，京津冀自贸试验区联席会议机制建立，发布"一地创新、三地互认"政策共享清单，累计推出六批 230项政务服务"同事同标"事项。(完) 该通知明确了在中国(北京)自由贸易试验区、中国(上海)自由贸易试验区、中国(广东)自由贸易试验区和 海南自由贸易港允许外商投资企业从事人体干细胞、基因诊断与治疗技术开发和技术应用，以用于产品 注册上市和生产。 在推进服务贸易自由便利方面，北京自贸试验区坚持"内外一致"原则，在外资金融机构开展新金融服 ...

Investment Rating - The report indicates a positive outlook for the life sciences industry, emphasizing the competitive advantage gained through artificial intelligence (AI) adoption [10][11]. Core Insights - The life sciences sector is leading in AI application, with 86% of companies believing they can embrace AI for competitive advantage, and 97% have already improved operations through AI [10][11]. - Despite the potential, many companies face challenges in achieving high returns on AI investments, with a significant portion only reaching break-even or low returns [7][8]. - The report outlines a structured framework for AI transformation in three phases: empowering employees, integrating AI into workflows, and evolving operational models [21][59]. Summary by Sections Introduction - The introduction highlights the transformative potential of AI in the life sciences industry, emphasizing the need for innovation in operations and value creation [16][17]. Overview - AI is recognized as a significant competitive advantage, with initial implementation results being encouraging [10][11]. - A well-adapted organizational structure is linked to higher investment returns [10]. Research Findings - The report reveals that 73% of companies have improved efficiency through AI, while 39% have enhanced financial performance [67]. - Data issues, including silos and quality concerns, are identified as major challenges in AI implementation [32][40]. Building Intelligent Life Sciences Enterprises - The report discusses the importance of integrating AI into daily operations and the need for a mixed organizational structure to drive innovation [24][41]. - Companies are encouraged to develop a culture that supports continuous learning and collaboration to maximize AI's potential [48]. Phase One: Empowering Employees - In this phase, companies focus on identifying areas where AI can automate tasks and improve workflows [66]. - Nearly three-quarters of respondents reported efficiency gains from AI, with a significant number also noting improvements in financial health [67]. Phase Two: Integrating AI into Workflows - Companies are advised to embed AI into various functions, enhancing operational efficiency and decision-making processes [61][64]. - The integration of AI should be aligned with business objectives to ensure strategic relevance [73]. Phase Three: Evolving Operational Models - The final phase emphasizes the need for companies to adapt their business models and ecosystems to leverage AI effectively [61][62]. - Organizations should focus on building trust in AI systems and ensuring compliance with ethical standards [48]. Key Recommendations - The report suggests that life sciences companies should prioritize developing a comprehensive AI strategy that aligns with business goals and stakeholder needs [48]. - Establishing a flexible and scalable technology infrastructure is crucial for maximizing AI's long-term value [48]. Conclusion - The life sciences industry is positioned to harness AI for significant advancements, but companies must address data challenges and cultivate a supportive culture to fully realize AI's benefits [42][43].

0:00 秋色初染，松花江畔，碧波轻抚堤岸，夕阳为松浦大桥镀上一层金晖。 水波荡漾间，松花江沿岸的百年历史风貌与现代都市景致交相融合，以这条江为轴线，江两岸产业兴、生态 美、万物生的鲜活图景，正沿着广袤的黑龙江大地舒展铺陈。 松花江畔。人民网 徐成龙摄 "十四五"以来，黑龙江省持续提升粮食综合生产能力。2024年，全省粮食总产量达到1600.34亿斤，创历史新 高，连续15年位居全国第一，粮食总产量和增量均居全国首位。 全省新建重点文旅项目400多个，累计完成投资720亿元。2024年，全省接待游客量2.8亿人次、游客总花费 3701.2亿元，同比分别增长29.1%、67.1%。 踏上观景台，只见先进的自动遥感无人机方舱及地面监测设备已经投入运行，无人机的自动巡航监测结合风 云卫星遥感数据系统，形成了"卫星宏观监测、无人机中观巡护、地面仪器精准采集"的"空—天—地"三维立体农 情监测体系，为这片孕育中的稻海注入了科技的"生命力"。 "近年来，富锦市大力发展农业新质生产力，推动卫星遥感与农业的深度融合。未来，我们将持续促进科技攻 关与产业应用协同，为农业插上'科技的翅膀'。"富锦市委副书记、市长赵尉凯介绍。 当 ...

中国证监会发布的《关于在科创板设置科创成长层 增强制度包容性适应性的意见》(以下简称《科创板 意见》)即将满三个月。 上交所副总经理王泊9月10日在出席"硬科硬客"新质生产力行业沙龙2025年会时表示，这不是简单的政 策调整，而是在特定的经济周期和市场需求下，为技术突破型企业送上的"及时雨"，让处于研发攻坚 期、暂未盈利但手握"硬核技术"的企业，不用等"盈利答卷"就能拿到"资本入场券"，努力打通硬科技与 资本市场对接的"最后一公里"。 首批32家存量未盈利企业直接入科创成长层。这些企业普遍处于研发密集期，具有较高的技术壁垒和市 场潜力，并展现出良好的发展动能。2025年上半年，上述企业合计营收同比增长37.79%，合计净利润 大幅减亏71.23亿元。 王泊还在前述场合透露，自科创板"1+6"政策发布以来，科创板新增受理15家企业IPO申请，其中4家为 未盈利企业，1家适用第五套标准。 对于科创板"1+6"政策落地后新增第五套IPO项目正式上市的时间，业内预计未来几个月内有可能出 现。 银河证券非银金融分析师张琦认为，科创成长层正式落地，其核心价值在于为国家科技自立自强战略提 供了强有力的资本市场制度支撑。 近 ...

中国证监会发布的《关于在科创板设置科创成长层 增强制度包容性适应性的意见》（以下简称《科创 板意见》）即将满三个月。 上交所副总经理王泊9月10日在出席"硬科硬客"新质生产力行业沙龙2025年会时表示，这不是简单的政 策调整，而是在特定的经济周期和市场需求下，为技术突破型企业送上的"及时雨"，让处于研发攻坚 期、暂未盈利但手握"硬核技术"的企业，不用等"盈利答卷"就能拿到"资本入场券"，努力打通硬科技与 资本市场对接的"最后一公里"。 对于科创板"1+6"政策落地后新增第五套IPO项目正式上市的时间，业内预计未来几个月内有可能出 现。 银河证券非银金融分析师张琦认为，科创成长层正式落地，其核心价值在于为国家科技自立自强战略提 供了强有力的资本市场制度支撑。 近3个月以来，科创板市场活跃度明显提升。数据显示，2025年6月18日至9月15日期间，科创板成交额 同比增长339.56%，平均换手率为216.73%，较2024年同期提升了116.73个百分点。 天风证券（601162）首席策略分析师、政策研究院院长吴开达表示，随着科创板成长层揭开面纱，我国 资本市场梯队建设进一步完善，预计未来或从精细化分层机制、上市 ...

9月15日，依据香港交易所《主板上市规则》18A章上市的未盈利生物科技企业药捷安康平开高走，一度狂飙124.10%，全天收于415.00港元/股，涨 115.58%。 9月10日，药捷安康发布公告称，公司核心产品替恩戈替尼（TT-00420）联合氟维司群治疗HR+/HER2-复发或转移性乳腺癌的II期临床试验，于2025年9月 10日获中国国家药监局默示许可。试验为开放标签、多中心研究，旨在评估联合疗法的安全性、疗效及药代动力学。 消息公布后，药捷安康股价连续4个交易日大涨，累计涨幅近500%。 公司同时根据上市规则第18A.08（3）条，风险提示：无法保证产品最终成功开发及商业化。 -1051.59 1671 -16.76% 749.65 09:30 12:00/13:00 16:00 额:104.89亿 1.03亿 除药捷安康外，多只18A板块个股大涨，脑动极光涨34.93%，MIRXES涨25.91%，三叶草生物涨18.67%，映恩生物涨13.18%，百奥赛图涨11.04%。 | 代码 | 名称 | 现价 | 涨跌幅 | 涨跌 | 5日涨跌幅 | | --- | --- | --- | --- | -- ...

Core Viewpoint - The article discusses the remarkable market performance of Yaojie Ankang (药捷安康), a biotech company that has achieved a market capitalization exceeding HKD 100 billion shortly after its IPO, despite not having any products approved for sale and currently operating at a loss [3][4]. Company Overview - Yaojie Ankang is an innovative drug company focused on developing small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases, currently in the clinical registration phase [5]. - The company's leading product, Tiengogatinib, is a selective multi-kinase inhibitor targeting key pathways including FGFR/VEGFR, JAK, and Aurora kinases, with potential applications in various difficult-to-treat solid tumors [5][6]. Clinical Development - As of June 30, 2025, Tiengogatinib is involved in nine clinical trials globally, with the fastest progress in cholangiocarcinoma, expected to complete its Phase II registration trial in China by the second half of 2025 [5][6]. - The global cholangiocarcinoma drug market is projected to grow from USD 2 billion in 2024 to USD 3.2 billion by 2027, with a compound annual growth rate (CAGR) of 16.2% from 2019 to 2024 [6]. Financial Performance - In the first half of the year, Yaojie Ankang reported zero revenue and a loss attributable to shareholders of HKD 123 million [8]. - In contrast, other biotech companies like Innovent Biologics and CanSino Biologics have reported significant profits and multiple approved products, highlighting a stark difference in financial health [8]. Market Sentiment - Investors express confusion over Yaojie Ankang's stock price surge, questioning the underlying logic behind the rapid increase in valuation without clear commercial prospects [9][10]. - Some investors speculate that the price movement may be driven more by speculative trading rather than fundamental company performance [10].

成交额突出个股方面，阿里巴巴成交226.05亿港元，上涨2.32%，云栖大会月底召开提振预期；腾讯控股成交105.36亿港元，股价持平；泡泡玛特成交 89.12亿港元，下跌6.43%。 恒生行业指数方面，非必需性消费行业指数上涨1.00%，能源业指数上涨0.83%，必需性消费行业指数上涨0.57%。跌幅方面，原材料业指数下跌1.08%， 综合企业指数下跌0.88%。 【导读】药捷安康狂飙近116%，近4个交易日累计涨近500%！带动18A板块大涨 9月15日，香港三大股指全线收涨，恒生指数涨0.22%，报26446.56点；恒生科技指数涨0.91%，报6043.61点；恒生中国企业指数涨0.21%，报9384.76点。 大市成交2901.95亿港元。南向资金净买入144.73亿港元。 泡泡玛特遭摩根大通下调评级至"中性"，股价逆市跌6.43%，收报259.00港元/股。 恒生指数成份股中33只上涨，52只下跌。药明生物涨6.47%，市场看好其创新药管线进展；理想汽车涨4.56%；农夫山泉涨4.11%，领涨蓝筹。 | 序号 | 名称 | 代码 | 现价 | 涨跌 | 涨跌幅 ▼ | 成交额 | 年初至今 | | ...

港股三大指数集体收涨，市场情绪继续高涨。尤其是恒生科技指数盘中一度涨至1.5%再度刷新阶段新高，最终收涨0.91%，恒生指数、国企指数 分别上涨0.22及0.21%。盘面上，大型科技股多数呈现上涨行情，阿里巴巴涨2.32%，小米、网易涨近2%，快手涨1%，美团涨0.83%，京东、腾讯 最终平收，百度则跌2.43%；内地电池行业股价上涨，锂电池股全天表现强势，龙头宁德时代大涨超7%创历史新高，超威动力、赣锋锂业、中航 创新、天齐锂业均涨超2%；生物科技股尾盘拉升，药捷安康飙涨115.58%表现最为抢眼，三叶草生物、药明生物、昭衍新药涨幅居前；汽车股、 煤炭股、新消费概念股、机器人概念股、港口及海运股齐涨。另一方面，影视股、纸业股跌幅居前，餐饮股、重型机械股、中资券商股、内房 股、濠赌股多数表现低迷，此外，全市场超20只个股跌幅在10%以上。(格隆汇) （原标题：港股收评：三大指数齐涨，恒科指再创阶段新高！锂电池股强势，生物医药股尾盘拉升） ...

Market Overview - A-shares showed mixed performance with the Shanghai Composite Index down 0.26%, Shenzhen Component Index up 0.63%, and ChiNext Index up 1.52% as of the market close on September 15, 2025. The total trading volume in the Shanghai and Shenzhen markets reached 22,774 billion [1]. ETF Performance - The Game ETF (159869) led the gains with an increase of 4.38%, followed by other Game ETFs and Film ETFs, all showing significant growth. The Smart Electric Vehicle ETF and Lithium Battery ETF also saw increases, indicating strong interest in these sectors [1]. - Conversely, the Communication sector faced declines, with the Communication ETF down 1.75%, leading the losses among ETFs [3]. Gaming Industry Insights - The gaming market in China experienced rapid revenue growth from January to July, with a total of 1,119 game licenses issued from January to August, marking a 20.8% year-on-year increase. The revenue for July was 29.1 billion yuan, up 4.7% year-on-year, indicating a positive trend in the gaming sector [2]. - The low valuation of the gaming sector, combined with new product launches and favorable regulatory policies, suggests potential for upward correction in the market [2]. Battery and Electric Vehicle Sector - Morgan Stanley highlighted CATL's breakthroughs in the European market, suggesting that its competitive edge will continue, especially as smaller competitors struggle in the energy storage sector. CATL is now considered one of the most attractively valued companies in the industry [2]. ETF Trading Activity - The Short-term Bond ETF (511360) had the highest trading volume at 33.2 billion yuan, followed by other bond ETFs, indicating strong investor interest in fixed-income products [4]. - The turnover rate for the Korean Semiconductor ETF (213310) was notably high at 406.66%, suggesting significant trading activity and interest in this sector [5]. Upcoming ETF Launch - The Huaan Hong Kong Stock Connect Biotechnology ETF (159102) is set to launch, focusing on Hong Kong-listed biotech companies. This ETF is designed for investors looking to capitalize on the long-term growth of the biotech sector, particularly in innovative drugs and aging population trends [8].